A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying

NCT01602549 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastroparesis

Interventions

DRUG: GSK962040 (25 mg tablet)
DRUG: Placebo

Sponsor

GlaxoSmithKline